Published in Medical Device Business Week, September 29th, 2004
The IPO is underwritten by Goldman Sachs JBWere and Wilson HTM, with Goldman Sachs JBWere acting as lead manager to the offer and Wilson HTM and ABN Amro Morgans serving as co-lead managers.
In addition to the fully underwritten issue of 30 million new shares, up to 8.3 million existing shares may be made available for general public applications. On completion of the offer, Acrux will have a market capitalization of $130.9 million.
The AUD $30 million raised from the sale of new shares will be used by Acrux...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.